Genomic Services for Bladder Cancer
Genomics is the study of the complete set of DNA sequences, including genes, regulatory regions, and non-coding regions, within an organism. Alfa Cytology utilizes our advanced genomics platform to support a broad range of genetic analysis applications for our clients. Our dedicated team of scientists aims to accelerate the discovery of novel therapeutic strategies bladder cancer.
Genomic in Bladder Cancer
Bladder cancer is a heterogeneous disease, characterized by diverse molecular subtypes and complex genetic alterations. Understanding the underlying genomic aberrations that drive bladder cancer initiation, progression, and response to therapy is paramount for developing effective targeted therapies and precision therapeutic strategies.
Fig.1 Molecular subtypes of muscle-invasive bladder cancer with associated clinicopathologic and genomic characteristics. (Matulay JT., et al. 2018)
The comprehensive analysis of the bladder cancer genome provides unprecedented insights into the driver mutations, oncogenic pathways, and potential therapeutic vulnerabilities, thereby revolutionizing our approach to diagnosis, prognosis, and therapy. The genomic characterization of bladder cancer has uncovered several key genes and pathways implicated in disease development and progression. Alterations in genes such as TP53, FGFR3, and PIK3CA have been frequently observed, contributing to dysregulated cell growth, survival, and invasion.
Our Services
We provide advanced genomic profiling services to help our clients explore and validate the mechanism of action of drugs, identify genetic alterations associated with drug response, and accelerate drug development.
Whole Exome Sequencing
We are able to effectively identify coding variants and mutations in the exome (the protein coding region that represents the genome) to help our clients gain insight into the inheritance of bladder cancer.
Targeted Gene Sequencing
We help our clients identify specific genetic variants and mutations associated with bladder cancer, help discover potential biomarkers and understand the molecular mechanisms driving the disease.
Whole Genome Sequencing
By utilizing next-generation sequencing (NGS) technology, we can help our clients examine the complete genetic makeup of their bladder cancer samples, including coding and non-coding regions, and discover novel genetic alterations, structural variants, and mutational features.
Bladder Cancer Genotyping
We provide genotyping services enable our clients to discover different molecular subtypes of bladder cancer and develop therapies that target different molecular subtypes.
Our Solutions Will Help You Achieve the Goals as Follows:
- Predicting response for bladder cancer therapies
- Biomarker discovery for bladder cancer
- Target identification for bladder cancer drug development
- Pharmacogenomics profiling for bladder cancer
- Variant detection genome-wide for bladder cancer
Project Workflow
Contact Us
Partnering with Alfa Cytology provides you with access to innovative genomics solutions and the expertise needed to advance your drug development efforts for bladder cancer. Contact us today to explore how our partnership can propel your drug development programs forward and contribute to the advancement of therapeutics for bladder cancer.
Reference
- Matulay J.T., Kamat A.M. Advances in risk stratification of bladder cancer to guide personalized medicine. F1000Res. 2018, 25, 7: F1000 Faculty Rev-1137.
For research use only. Not intended for any clinical use.
Related Services
